Medical/Pharmaceuticals
RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China
YANTAI, China, Oct. 29, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently announced that the marketing application of Taicercept ® for the treatment of generalized myasthenia gravis (gMG) has been officially...
2024-10-29 12:00
2474
The 21st World Congress of Chinese Medicine - Seminar on the Integration of Industry and Education in Cardiovascular and Cerebrovascular Diseases Kicks off in Paris
PARIS, Oct. 29, 2024 /PRNewswire/ -- On October 25, 2024, the 21st World Congress of Chinese Medicine (WCCM) commenced at the United Nations Educational, Scientific and Cultural Organization (UNESCO) Headquarters in Paris, France. A key highlight of the WCCM was the Seminar on the Integratio...
2024-10-29 11:01
2095
Innovent Announces Results of a Phase 2 Study of Picankibart (Anti-IL-23p19 Antibody) in Plaque Psoriasis, Showing Efficacy in Patients with Prior Inadequate Response to IL-17 Biologics
SAN FRANCISCO and SUZHOU, China, Oct. 29, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...
2024-10-29 07:57
3217
Clover Announces Positive Clinical Data for RSV Vaccine Candidate SCB-1019 Compared Head-to-Head Versus GSK's AREXVY
-- Head-to-head clinical results indicate a potential best-in-class combined efficacy & safety profile of non-adjuvanted bivalent RSV vaccine candidate (SCB-1019) -- -- RSV neutralizing antibodies for Clover's non-adjuvanted SCB-1019 matched GSK's AS01E-adjuvanted AREXVY in older adults, while d...
2024-10-29 06:32
4042
Lilly's Mounjaro® (tirzepatide) Approved in Hong Kong in KwikPen® Presentation for Chronic Weight Management and Type 2 Diabetes, Offering a New Option for the Treatment of Obesity, Overweight and Type 2 Diabetes
* Adults taking Mounjaro in a clinical trial lost on average 48 lb. at the highest dose1,2 * Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials6-12 * Mounjaro represents a new class of obesity and diabetes medicines and is expected to be ava...
2024-10-28 15:12
3412
/C O R R E C T I O N -- Seegene Inc./
In the news release, Seegene Holds Partner Executive Roundtable with Microsoft, and Springer Nature, Accelerating its Technology-Sharing Initiative, issued 24-Oct-2024 by Seegene Inc. over PR Newswire, we are advised by the company that the second photo and its caption should be removed as origina...
2024-10-28 12:50
5410
DKSH and FrontierView Publish Whitepaper on Southeast Asia as a Growth Accelerator for Global Healthcare Firms
DKSH and FrontierView, a business intelligence and advisory firm, published a whitepaper providing an in-depth assessment of the healthcare status of the Southeast Asia (SEA) region. The research collated in DKSH's whitepaper provides a comprehensive analysis of the regional healthcare landscape,...
2024-10-28 09:00
4894
PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint
PROVISION Study demonstrates significant economic and resource utilization advantages in FFRangio cohort compared to invasive wire-based FFR cohort WASHINGTON, Oct. 28, 2024 /PRNewswire/ -- Today at the Cardiovascular Research Foundation's annual Transcatheter Cardiovascular Therapeutics (TCT) c...
2024-10-28 02:56
2071
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
GAITHERSBURG, Md., Oct. 25, 2024 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for i...
2024-10-25 20:30
2837
Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients
44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt TEWKSBURY, Mass., Oct. 25, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced im...
2024-10-25 19:20
2313
Brinc Hosts Its 4th Successful Asia Health Innovation Summit 2024, as Part of StartmeupHK Festival, Curated by InvestHK
HONG KONG, Oct. 25, 2024 /PRNewswire/ -- The Asia Health Innovation Summit 2024
2024-10-25 18:34
2683
Ribbon of Hope: A Collaborative Cancer Support Initiative by BIG Pharmacy and CARiNG Pharmacy
JOHOR BAHRU, Malaysia, Oct. 25, 2024 /PRNewswire/ -- BIG CARiNG Group proudly announces the unveiling of its revolutionary Cancer Support Program, namely "Ribbon of Hope" for you and those you care for at the Biggest Health & Beauty Expo held at Mid Valley Southkey. This initiative is designed to...
2024-10-25 15:25
2497
Everest Medicines Announces the Launch of VELSIPITY® in the Guangdong-Hong Kong-Macau Greater Bay Area, Offering a New Option for Moderately to Severely Active Ulcerative Colitis Patients
SHANGHAI, Oct. 25, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that, through the "Hong Kong and Ma...
2024-10-25 07:40
2551
Volpara Health Surpasses 300 Peer-Reviewed Papers
Milestone reinforces readership in AI-powered breast cancer detection WELLINGTON, New Zealand, Oct. 25, 2024 /PRNewswire/ -- Volpara Health, a Lunit company and global leader in artificial intelligence (AI)-powered breast health solutions, has reached a significant milestone: the publication ...
2024-10-25 00:00
2686
Frost & Sullivan Honors Industry Leaders with Prestigious 2024 Best Practices Awards
Top Innovators Recognized for Outstanding Achievements at Semiannual Awards Gala SAN ANTONIO, Oct. 24, 2024 /PRNewswire/ -- The 2024 Frost & Sullivan Best Practices Awards Gala, hosted at the JW Marriott Tucson Starr Pass Resort in Tucson, AZ, brought together the best in business to celebrate tra...
2024-10-24 22:00
1750
EpiVax and CUBRC Awarded FDA Contract Worth $2M for Development of Control Peptides for Immunogenicity Risk Assessment Assays Supporting Regulatory Filings of Generic Peptide Drugs
PROVIDENCE, R.I., Oct. 24, 2024 /PRNewswire/ -- EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announce today that they have been awarded a two-year,$2 million contract (#75F40124C00094) from the Office of Generic Drugs (OGD) of the Food and Drug Administration (FDA) to develop standardized co...
2024-10-24 21:05
2457
Besmile Announces RMB 1 Million Donation to Support Shanghai 9th People's Hospital's Dental Service Development
SHANGHAI, Oct. 24, 2024 /PRNewswire/ -- Dental service provider Besmile proudly announces a donation ofRMB 1 million to Shanghai 9th People's Hospital, reinforcing its commitment to enhancing dental service capabilities within the industry. The fund will help elevate the medical facilities to cre...
2024-10-24 20:20
5681
The 2024 Seminar on International Communication of Chinese Medicine and Yi Medicine Big Health Industry Development Promotion Conference Held in Chuxiong, Yunnan Province
CHUXIONG, China, Oct. 24, 2024 /PRNewswire/ -- The 2024 Seminar on International Communication of Chinese Medicine and Yi Medicine Big Health Industry Development Promotion Conference was held in Chuxiong,Yunnan Province onOctober 21. The event was co-sponsored by the China Association of Chinese...
2024-10-24 15:48
5307
Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations
Pierre Fabre Laboratories Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-002/VERT-002, an Innovative Targeted Therapy Intended to Treat Non-Small Cell Lung Cancer with MET Alterations PFL-002/VERT-002 is a monoclonal antibody with a novel and differentiated mechanism of action,...
2024-10-24 15:15
2673
Founder of Hua Medicine Dr. Li CHEN was awarded the "C.C. Tan Life Science Industrialization Award"
SHANGHAI, Oct. 24, 2024 /PRNewswire/ -- The 17th "C.C. Tan Life Science Award" ceremony was held inShenyang, China, on October 9th. Dr. Li CHEN, Founder and Chief Executive Officer of Hua Medicine, was awarded the "C.C. Tan Life Science Industrialization Award". C.C. Tan Life Science Award has th...
2024-10-24 13:16
5199
Week's Top Stories
Most Reposted
DBS is First Bank in Asia Pacific to Pilot Visa Intelligent Commerce for Everyday Payments
[Picked up by 320 media titles]
2026-02-16 10:00
Marina Bay precinct partners UOB, Marina Bay Sands and Singapore Tourism Board, together with Disney Cruise Line, to illuminate Singapore's skyline with a fireworks sky show
[Picked up by 319 media titles]
2026-02-19 14:30
Little Artists Art Studio, Singapore Shines at Art Capital 2026
[Picked up by 278 media titles]
2026-02-17 19:12
Kung Fu Meets Spring -- Unitree Spring Festival Gala Robots Present "Cyber Real Kung Fu" in the Year of the Horse
[Picked up by 257 media titles]
2026-02-17 14:16SMU MBA Rises in FT Global Rankings, Excelling in ESG, Salary and Value-for-Money
[Picked up by 251 media titles]
2026-02-16 08:00